Eton Pharma - Small Cap That's Climbing

Barchart · 11/26 07:00

Summary

  • Eton Pharmaceuticals (ETON) has shown exceptional price appreciation, gaining 224.93% since a Trend Seeker buy signal on 7/17, supported by strong technical indicators.

  • The company focuses on developing and commercializing pharmaceutical products for rare diseases, with significant revenue and earnings growth expected in the coming years.

  • Barchart's technical indicators show 100% buy signals, a 356.79 Weighted Alpha, and a 210.80% gain in the last year, with strong support levels.

  • Analysts' sentiment is positive with price targets between $11 and $15, and various ratings from Wall Street firms and investor platforms indicating a buy.

The Chart of the Day belongs to the pharmaceutical company Eton Pharmaceuticals (ETON) . I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical buy signals, highest Weighted Alpha, superior current momentum and having a Trend Seeker buy signal then used the Flipchart feature to review the charts for consistent price appreciation. Since the Trend Seeker signaled a buy on 7/17 the stock gained 224.93%.

ETON Price vs Daily Moving Averages:

 

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois. 

Barchart's Opinion Trading systems are listed below. Please note that the Barchart Opinion indicators are updated live during the session every 20 minutes and can therefore change during the day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the Barchart.com website when you read this report.

Barchart Technical Indicators:

  • 100% technical buy signals
  • 356.79 Weighted Alpha
  • 210.80% gain in the last year
  • Trend Seeker buy signal
  • 1.25 - 60 month Beta
  • Above its 20, 50 and 100 day moving averages
  • 11 new highs and up 51.36% in the last month
  • Relative Strength Index 77.60%
  • Technical support level at $10.74
  • Recently traded at $11.87 with 50 day moving average of $8.09

Fundamental Factors:

  • Market Cap $290 million
  • Revenue expected to grow 20.64% this year and another 81.27% next year
  • Earnings are estimated to increase by 464.00% next year

Analysts and Investor Sentiment -- I don't buy stocks because everyone else is buying but I do realize that if major firms and investors are dumping a stock it's hard to make money swimming against the tide:

  • Wall Street analyst gave 1 strong buy and 1 buy opinion on the stock
  • Analysts' price targets are between $11 and $15 with a consensus of $13 about a 10% discount
  • Value Line give the stock its above average rating of 2
  • CFRAs MarketScope rates the stock a buy
  • MorningStar gives the stock its average rating of 3 with a Fair Value of $13 or 12% under valued
  • 2,490 investors monitor the stock on Seeking Alpha

Additional disclosure: The Barchart Chart of the Day highlights stocks that are experiencing exceptional current price appreciation. They are not intended to be buy recommendations as these stocks are extremely volatile and speculative. Should you decide to add one of these stocks to your investment portfolio it is highly suggested you follow a predetermined diversification and moving stop loss discipline that is consistent with your personal investment risk tolerance and reevaluate your stop losses at least on a weekly basis.


On the date of publication, Jim Van Meerten did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.